You just read:

DARZALEX® (Daratumumab) Shows Overall Survival Benefit and Continued Improvement in Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Who Are Ineligible for Transplant

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Dec 09, 2019, 16:48 ET